Latest News & Features
Careers
Sapna Palla joins the firm in New York, bringing significant experience in complex life sciences and IP disputes to a growing practice. 12 November 2024
Americas
As Donald Trump celebrates a second term, LSIPR looks at how key IP areas could be affected ahead of his return to the Oval Office. 7 November 2024
Asia
Free trade zones in Beijing, Shanghai, Guangdong, and Hainan are designed to attract capital into China’s fast-growing healthcare sectors, says Li Mi of Lusheng. 7 November 2024
Americas
Well-drafted contracts and ironclad tech security can save time and money when an ex-employee steals IP ‘like sugar packets in Starbucks’, finds Tom Phillips. 7 November 2024
Americas
On January 10 this year, the director of the USPTO issued new guidelines on enablement under 35 U.S.C §112. In recent years, the landscape of patent law in the United States has undergone a significant shift, with courts adopting a more stringent stance on the criteria of enablement and written description. 5 November 2024
Americas
A US biopharma firm must pay the damages to Sandoz over a long-running dispute over lung therapy | New Jersey district judge had ordered the pair to “meet and confer” in a September judgment, but the parties couldn’t agree. 5 November 2024
Americas
The 47th US president will need to address the thorny issues of non-competes, patent rights and drug pricing. 5 November 2024
Americas
A jury in Delaware unanimously dismissed all allegations of misappropriation against Inhibrx, a Sanofi-owned biotech firm | Case stemmed from a previous arbitration involving the chief scientific officer of Inhibrx | Jury found no evidence supporting opponents claims, awarding the plaintiff $0 damages. 5 November 2024
Americas
New hire specialises in guiding life sciences and health tech clients through compliance issues | Work includes US regulations, including those enforced by the FDA, Drug Enforcement Administration and the Office of Inspector General. 31 October 2024
Europe
European Commission says fine “proportionate and necessary” after Teva spread misleading information about rival’s product | Teva says it is “deeply disappointed” and will appeal. 31 October 2024